Market Place
Sourcing Support
Trethera Presentation At Rare Neuroimmune Disorders Symposium Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Trethera Receives $2M NIH Grant For Pediatric ADEM Treatment Research
16 Jul 2024 //
GLOBENEWSWIRE
National Institute of Health to Fund Preclinical Development of TRE-515
25 Sep 2023 //
GLOBENEWSWIRE
Dr. Michael Levy, Joins Trethera Scientific Advisory Board
05 Sep 2023 //
GLOBENEWSWIRE
Trethera Receives NIH Grant for Development in the Pediatric Neurologic Disease
14 Aug 2023 //
GLOBENEWSWIRE
Trethera Announces Appointment of Laurent Dubois to Board of Directors
15 Feb 2023 //
GLOBENEWSWIRE
Trethera Announce Presentation for Research in Multiple Sclerosis Annual Meeting
24 Jan 2023 //
GLOBENEWSWIRE
Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors
18 Jan 2023 //
GLOBENEWSWIRE
Trethera Receives $1.6 Million National Eye Institute Grant for TRE-515
19 Oct 2022 //
GLOBENEWSWIRE
Trethera Announces Multiple Sclerosis Treatment Poster Presentation
04 Oct 2022 //
GLOBENEWSWIRE
U.S. Patent Office Issues Trethera Composition of Matter Patent Covering TRE-515
20 Sep 2022 //
GLOBENEWSWIRE
Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Contro
07 Sep 2022 //
GLOBENEWSWIRE
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515
30 Aug 2022 //
GLOBENEWSWIRE
Trethera Receives U.S. PON of Allowance Covering TRE-515 Structural Claims
17 Aug 2022 //
GLOBENEWSWIRE
Trethera Announces FDA ODD Granted to TRE-515 for Demyelinating Optic Neuritis
09 Aug 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.